Perspectives in the Treatment of or Mutated Metastatic Colorectal Cancer Patients

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Mar 19

PMID 33738249

Citations 3

Authors

Gerardo Rosati

Giuseppe Aprile

Debora Basile

Antonio Avallone

Affiliations

Soon will be listed here.

Citing Articles

, and Mutational Profile of Colorectal Cancer in a Series of Moroccan Patients.

El Zaitouni S, Laraqui A, Ghaouti M, Benzekri A, Kettani F, Bajjou T Cancer Control. 2024; 31:10732748241262179.

PMID: 38875469 PMC: 11179507. DOI: 10.1177/10732748241262179.

RAS/RAF mutations and microsatellite instability status in primary colorectal cancers according to HER2 amplification.

Lee S, Oh H Sci Rep. 2024; 14(1):11432.

PMID: 38763942 PMC: 11102903. DOI: 10.1038/s41598-024-62096-x.

Colorectal Cancer Heterogeneity and the Impact on Precision Medicine and Therapy Efficacy.

Rosati G, Aprile G, Colombo A, Cordio S, Giampaglia M, Cappetta A Biomedicines. 2022; 10(5).

PMID: 35625772 PMC: 9138254. DOI: 10.3390/biomedicines10051035.

References

Romero D . Two new agents target KRAS G12C. Nat Rev Clin Oncol. 2019; 17(1):6. DOI: 10.1038/s41571-019-0304-3. View

Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu R . Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol. 2017; 29(1):44-70. DOI: 10.1093/annonc/mdx738. View

Sorich M, Wiese M, Rowland A, Kichenadasse G, McKinnon R, Karapetis C . Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol. 2014; 26(1):13-21. DOI: 10.1093/annonc/mdu378. View

Ebert P, Cheung J, Yang Y, McNamara E, Hong R, Moskalenko M . MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade. Immunity. 2016; 44(3):609-621. DOI: 10.1016/j.immuni.2016.01.024. View

Shiratori H, Kawai K, Hata K, Tanaka T, Nishikawa T, Otani K . The combination of temsirolimus and chloroquine increases radiosensitivity in colorectal cancer cells. Oncol Rep. 2019; 42(1):377-385. DOI: 10.3892/or.2019.7134. View

Furuse J, Kurata T, Okano N, Fujisaka Y, Naruge D, Shimizu T . An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors. Cancer Chemother Pharmacol. 2018; 82(3):511-519. PMC: 6105164. DOI: 10.1007/s00280-018-3618-4. View

Bogaert J, Prenen H . Molecular genetics of colorectal cancer. Ann Gastroenterol. 2014; 27(1):9-14. PMC: 3959535. View

Ryan M, Corcoran R . Therapeutic strategies to target RAS-mutant cancers. Nat Rev Clin Oncol. 2018; 15(11):709-720. DOI: 10.1038/s41571-018-0105-0. View

Koncina E, Haan S, Rauh S, Letellier E . Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges. Cancers (Basel). 2020; 12(2). PMC: 7072488. DOI: 10.3390/cancers12020319. View

10.

Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L . Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014; 371(17):1609-18. DOI: 10.1056/NEJMoa1403108. View

11.

Van Cutsem E, Martinelli E, Cascinu S, Sobrero A, Banzi M, Seitz J . Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study. Oncologist. 2018; 24(2):185-192. PMC: 6369948. DOI: 10.1634/theoncologist.2018-0072. View

12.

Eng C, Kim T, Bendell J, Argiles G, Tebbutt N, Di Bartolomeo M . Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2019; 20(6):849-861. DOI: 10.1016/S1470-2045(19)30027-0. View

13.

Reita D, Bour C, Benbrika R, Groh A, Pencreach E, Guerin E . Synergistic Anti-Tumor Effect of mTOR Inhibitors with Irinotecan on Colon Cancer Cells. Cancers (Basel). 2019; 11(10). PMC: 6826690. DOI: 10.3390/cancers11101581. View

14.

Zarkavelis G, Boussios S, Papadaki A, Katsanos K, Christodoulou D, Pentheroudakis G . Current and future biomarkers in colorectal cancer. Ann Gastroenterol. 2017; 30(6):613-621. PMC: 5670280. DOI: 10.20524/aog.2017.0191. View

15.

Van Cutsem E, Mayer R, Laurent S, Winkler R, Gravalos C, Benavides M . The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer. Eur J Cancer. 2017; 90:63-72. PMC: 7493695. DOI: 10.1016/j.ejca.2017.10.009. View

16.

Le D, Uram J, Wang H, Bartlett B, Kemberling H, Eyring A . PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015; 372(26):2509-20. PMC: 4481136. DOI: 10.1056/NEJMoa1500596. View

17.

Hong D, Fakih M, Strickler J, Desai J, Durm G, Shapiro G . KRAS Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med. 2020; 383(13):1207-1217. PMC: 7571518. DOI: 10.1056/NEJMoa1917239. View

18.

Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D . FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2003; 22(2):229-37. DOI: 10.1200/JCO.2004.05.113. View

19.

Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D . Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012; 483(7387):100-3. DOI: 10.1038/nature10868. View

20.

Seligmann J, Fisher D, Smith C, Richman S, Elliott F, Brown S . Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials. Ann Oncol. 2016; 28(3):562-568. DOI: 10.1093/annonc/mdw645. View